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Virus and host genomic, molecular, and cellular interactions during Marek’s
disease pathogenesis and oncogenesis
M. C. McPherson and M. E. Delany1
Department of Animal Science, University of California, Davis, CA 95616
ABSTRACT Marek’s Disease Virus (MDV) is a chicken
alphaherpesvirus that causes paralysis, chronic wasting,
blindness, and fatal lymphoma development in infected,
susceptible host birds. This disease and its protective
vaccines are highly relevant research targets, given their
enormous impact within the poultry industry. Further,
Marek’s disease (MD) serves as a valuable model for
the investigation of oncogenic viruses and herpesvirus
patterns of viral latency and persistence—as pertinent
to human health as to poultry health. The objectives
of this article are to review MDV interactions with its
host from a variety of genomic, molecular, and cellu-
lar perspectives. In particular, we focus on cytogenetic
studies, which precisely assess the physical status of
the MDV genome in the context of the chicken host
genome. Combined, the cytogenetic and genomic re-
search indicates that MDV-host genome interactions,
specifically integration of the virus into the host telom-
eres, is a key feature of the virus life cycle, contributing
to the viral achievement of latency, transformation, and
reactivation of lytic replication. We present a model
that outlines the variety of virus-host interactions, at
the multiple levels, and with regard to the disease
states.
Key words: chicken, genome integration, Marek’s disease, fluorescence in situ hybridization, telomere
2016 Poultry Science 95:412–429
http://dx.doi.org/10.3382/ps/pev369
INTRODUCTION
Marek’s Disease – Characteristics and
History
Marek’s disease (MD) is a complex, immunosuppres-
sive disease characterized by paralysis, chronic wast-
ing, lymphoma development in the viscera and mus-
culature, and blindness in chickens (Davison and Nair,
2004; Jarosinski et al., 2006) infected by Marek’s dis-
ease virus (MDV) (Churchill and Biggs, 1967). MD
symptoms vary in severity based on virus strain as well
as bird genotype and vaccination status with death
occurring in susceptible, non-immunized chickens. In
1907, Jozsef Marek, a Hungarian veterinarian, first re-
ported the common symptoms of “classic” MD, namely
polyneuritis (Marek, 1907). Polyneuritis was later cou-
pled with other symptoms as part of the same dis-
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ease and named after the veterinarian in 1960 (Gimeno
et al., 1999). MDV was classified as an alphaherpesvirus
based on repeat structures identified through electron-
microscopy (Cebrian et al., 1982) and confirmed by
virus sequencing studies (Lee et al., 2000a; Tulman
et al., 2000).
When first identified as a virus-induced disease, the
characteristic feature was peripheral nerve inflamma-
tion. At present, more virulent strains of MDV induce a
particularly severe range of symptoms, including strong
immunosuppression, tumors, and neurological disorders
(Gimeno et al., 1999). Increased MDV virulency induces
dramatic thymic and bursal atrophy (Calnek et al.,
1998) and macrophage death due to viral replication
(Barrow et al., 2003). The disease is controlled with
MD vaccines, which are either mono- or bivalent, as
well as breeding for resistance and improved poultry
management practices. Specific mechanisms of MDV
immunization through use of vaccines are not com-
pletely clear. The innate immune response is induced,
but the cytotoxic response is minimal as compared to
response to other viruses (Markowski-Grimsrud and
Schat, 2002). Ever-increasing virulence of MDV has
led to growing concerns over potential breaks in vac-
cinal protection due to the fact that evolution towards
higher virulency in response to vaccine usage has oc-
curred in the past. This concern is elevated by the issue
of reduced genetic diversity across much of the poul-
try industry (Nair, 2005; Muir et al., 2008). Improved
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Table 1. A review of Marek’s disease virus serotypes and their features.
Genome size Annotated vTR vIl8 pp38 Meq Telomeric
Serotype Strain Status (kb)g ORFs∗ geneh,i,j gene gene oncogene repeatsk
1 GAa Virulent 174 103 + + + + +
1 Md5b Very virulent 177.8 103 + + + + +
1 Md11c,d Very virulent 178 99 + + + + +
1 Rispens/CV1988d Attenuated 178.3 102 + +/NF +/NF +/NF +
2 SB-1e Non oncogenic 165.9 75 − +/NF +/NF − +
3 HVTf Non oncogenic 160 75 − − − − +
Open reading frames (ORFs), viral telomerase RNA (vTR), viral interleukin-8 (vIL-8), phosphoprotein 38 (pp38), + (plus) =
present; − (minus) = absent; +/NF = present but non-functional.
aLee et al., 2000a,b; bTulman et al., 2000; cNiikura et al., 2006; dSpatz et al., 2007; eSpatz and Schat, 2011; fKingham et al., 2001;
gWilson and Coussens, 1991; hFragnet et al., 2003; iFragnet et al., 2005; jTrapp et al., 2006; kKishi et al., 1988.
vaccination strategies and understanding of the virus
and the vaccines remain important areas of study to
prevent or reduce outbreaks.
Marek’s Disease Virus - Genome Structure
The human herpesvirus 6 (HHV-6) and Epstein-
Barr virus (EBV) share a number of features with
MDV (Delecluse et al., 1993b; Gomples and Macaulay,
1995; Arbuckle et al., 2010), including an associa-
tion with lymphoproliferative cancers (Kaschka-Dierich
et al., 1976; Daibata et al., 1998), emphasizing that
the chicken is an important medical model organism for
the study of human virus-induced diseases and cancers.
This is, of course, in addition to the importance of MDV
research, given its impact on chicken populations world-
wide. MDV, also known as gallid herpesvirus 2, is a
member of the genus Mardivirus. Three serotypes have
been identified: 1) oncogenic serotype 1 strains (GA,
Md11, Md5), 2) non-oncogenic serotype 2 strain (SB-
1), and 3) serotype 3 herpesvirus of turkeys (HVT).
MDV serotypes are identified by monoclonal antibod-
ies produced against them by the host immune sys-
tem after infection (Lee et al., 1983). Serotypes 2 and
3 are antigenically related to serotype 1 strains, but
do not induce the disease phenotype or lymphomas in
chicken (Kato and Hirai, 1985; Lee et al., 2000b). The
first sequence-based assessment of the serotypes found
that MDV serotype 1 and HVT had collinear genomes
and similar structures to that of herpes simplex virus 1
(HSV-1) and varicella zoster virus (VZV), which in-
dicated an alphaherpesvirus classification (Buckmaster
et al., 1988). Several full-genome sequence and compar-
ative genomic studies have been conducted since this
initial sequencing work (Lee et al., 2000a; Tulman et al.,
2000; Izumiya et al., 2001; Kingham et al., 2001; Spatz
et al., 2007), providing a base for further comparative
genomic studies in MDV research as well as tools for cy-
togenetic analyses of the virus (Table 1). Viral cloning,
or the introduction of overlapping viral genomic frag-
ments into a cosmid or bacterial artificial chromosome
(BAC) vector, has proven to be an invaluable research
tool for investigations of the MDV genome sequence as
well as studies of MDV pathogenesis and tumorigene-
sis (Zelnik, 2003). MDV serotype 1 was the first viral
serotype cloned and mutated to investigate a viral gene
function; specifically, the gB genes were deleted and the
impact on viral function was examined in vitro (Schu-
macher et al., 2000).
The MDV genome is 175 to 180 kb, depending on the
strain, with an episomal or circular structure when in-
dependent of the host genome. The genome consists of
several regions, namely the unique long (UL) and short
(US) regions flanked by terminal repeats long (TRL)
and short (TRS) and internal repeats long (IRL) and
short (IRS) (Figure 1). Genome structure and gene
content of each region are similar among all MDV
serotypes, but there exist key differences (Table 1).
Oncogenic serotype 1 is defined by the presence of the
Meq oncogene and other unique genes including pp38,
vIL8, and vTR in repeat regions, particularly TRL (Lee
et al., 2000b; Nair, 2005). These genes also largely con-
tribute to the unique biological features of MDV, such
as targeting and transformation of activated T lympho-
cytes. The viral genes that are unique to each particular
avian herpesvirus are located in the repeat regions of
the genome as revealed by sequence comparisons (Zel-
nik, 2003). Sequence analysis of the serotype 1 MDV
termini identified 2 different cleavage sites involved in
the mature viral packaging process following genome
replication. The “classical” cleavage site of MDV is up-
stream of the DR1 motif site and results in a genome
termini with telomeric repeats (TTAGGG)n (Volkening
and Spatz, 2013).
MDV Infection Stages
Figure 2 provides an overview model of MDV in-
fection, pathogenesis, and transformation, incorporat-
ing molecular, cellular (including cytogenetic), and ge-
nomics knowledge to-date. MDV infection begins with
inhalation of infectious virions from shed feather dan-
der. Within 24 h after contact in the lungs, the virus
is present in the spleen, thymus, and bursa of the
host bird (Schat et al., 1984). The viral transition
from lung to lymphoid organs is attributable to in-
fected macrophages (Calnek, 2001; Barrow et al., 2003),
which transfer the virus to B lymphocytes, or direct
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Figure 1. Schematic of ‘free’ Marek’s disease virus: linear and episomal genomes. Diagrams of free (non-integrated) viral genome in the linear
and circularized (episomal) forms are depicted. The MDV genome consists of double-stranded DNA (all serotypes) and is approximately 180kb
(serotype 1). The MDV genome structure is divided into long and short sections, similar to other alpha-herpesviruses. Both the long and short
(denoted by L and S subscripts, respectively) sections consist of: unique (U) sequence regions, blocks of sequences that are corresponding inverted
repeats of one another (terminal (TR) and internal (IR)), telomeric DNA sequence ((TTAGGG)n) blocks, and alpha-like sequence which includes
telomeric DNA sequence (Kishi et al., 1988; Lee et al., 2000a; Tulman et al., 2000). The colored blocks indicate the locations of the (TTAGGG)n
telomeric sequence repeats (green) and the blocks of inverted sequences within the long (dark blue, TRL and light blue, IRL) and short (dark
purple, IRS and light purple, TRS) sections. The straight lines within the long and short sections represent the unique sequence regions (UL and
US). The (TTAGGG)n sequences, viral telomerase RNA (vTR) gene and Meq gene locations are indicated by arrows (see orange block notation).
Notably, upon circularization of the genome, the two blocks of telomeric sequence repeats are brought together. Table 1 describes key differences
and similarities between the MDV serotypes with regard to presence/absence and/or functionality of viral telomeric DNA sequence and the vTR
and Meq genes.
infection of B lymphocytes (Baaten et al., 2009). All
movement of MDV within an infected host bird is
cell-associated, i.e., cell-free, unenveloped virus is not
infective (Nazerian et al., 1968). Virulent MDV un-
dergoes 4 overlapping infection stages, having critical
consequences that contribute to viral persistence and
pathogenesis in the host: early cytolytic, latent, late
cytolytic, and transformation (Biggs, 1968; Adldinger
and Calnek, 1973; Osterrieder et al., 2006). In the cy-
tolytic stage, the virus replicates in macrophages and
B and T lymphocytes. Following the lytic phase of in-
fection, latent (non-replicating) infection is established
around 7 d post-infection (dpi) (Arumugaswami et al.,
2009; Baigent and Davison, 2004; Trapp et al., 2006).
Latently-infected T lymphocytes are capable of being
transformed, typically between 14 and 21 dpi, result-
ing in lymphomas in the visceral organs (Witter, 1997;
Calnek, 2001; Burgess and Davidson, 2002; Nair, 2005;
Osterrieder et al., 2006; Trapp et al., 2006).
MDV Transmission
Horizontal transmission is accomplished through
shedding of infectious MDV virions in feather dan-
der (Beasley et al., 1970). Viral shedding by an in-
fected host bird occurs after latent MDV reaches and
infects the feather follicle epithelium (FFE) via pe-
ripheral lymphocytes circulating in the blood (John-
son et al., 1975). The reactivated MDV in the FFE
produces mature cell-free virions (Nazerian and Wit-
ter, 1970) that can persist in the external environ-
ment for wk to mo (Calnek, 2001; Osterrieder et al.,
2006). Enveloped herpesvirus particles were first de-
tected in the FFE in an electron microscopy study
of JM-strain infected birds (Calnek et al., 1970). In-
fectious viral particles are first detected in shed dan-
der around 8 dpi (Jarosinski, 2012) and viral load in
dander increases up to 28 dpi. In vivo studies have
demonstrated data that suggest that functional copies
of the viral genes US2, UL13, and glycoprotein C are
all required for horizontal MDV transmission, although
their exact functions are yet to be identified (Jarosinski
et al., 2007).
MD Vaccines – Impact and Mechanisms
The 1960s were marked by a major increase in poul-
try loss due to MD (Witter, 1997). Remarkably, the
discovery of the oncogenic herpesvirus etiology was fol-
lowed by development of an effective vaccine, specifi-
cally live HVT (Churchill and Biggs, 1968; Churchill
et al., 1969; Okazaki et al., 1970), in the early 1970s.
Field strain virulency increased through the late 1970s
resulting in more outbreaks until bivalent vaccines were
employed (SB-1 + HVT) in the 1980s and later the at-
tenuated serotype 1 Rispens/ CV1988 vaccine (Rispens
et al., 1972; Petherbridge et al., 2003), all of which
are cell-associated viruses. The MD vaccines were the
first vaccines capable of preventing virus-induced can-
cer (Calnek, 1986). The attenuated Rispens vaccine was
developed through serial in vitro passaging of serotype
1 MDV, a process known to reduce the ability of MDV
strains to grow in vivo as well as to amplify tandem
direct repeats in the IR regions of the viral genome
(Maotani et al., 1986). The Rispens vaccine is the most
effective against very virulent (vv) and very virulent
plus (vv+) MDV to date, and is safe for inoculation
in susceptible birds. Inoculation of birds with HVT
and SB-1 also prevents MD, but is generally less ef-
fective against vv and vv+ strains. MD vaccines are
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Figure 2. A model of Marek’s disease virus and chicken host genomic, molecular, cellular, and tissue interactions during early infection,
pathogenesis, and transformation. Three highly simplified, inter-connected routes are depicted by arrows: green, MDV-host genome status;
blue, virus movement internally (host cells and tissues) and externally (dander in the environment); light red, transformation and tumorigenesis.
Along these routes, the light gray pentagons with text and diagrams indicate the organs involved in the disease and the hexagons indicate MDV
serotype pathways (blue, all MDV serotypes; green, virulent MDV vs. MD vaccine; light red, oncogenic MDV). The overlapping disease stages
(cytolytic, latent, reactivated, transformed) and virus-host genome status (see main text for cytogenetic viral phenotype explanations) are indicated
by the bold font along the routes: cytolytic, circularized-episomal MDV (cytogenetic chromosome-associated phenotype); cytolytic, episomal
and linear telomere-integrated MDV (cytogenetic chromosome-associated and telomere-integrated phenotype); latency, telomere-integrated MDV
(cytogenetic telomere-integrated only phenotype); reactivation or return to cytolytic phase; transformed cells, (mostly cytogenetic telomere-
integrated only phenotype). In susceptible research chickens, tumors can develop as early as 21 d post-infection. See main text for outline of the
overlapping timing of early cytolytic, latency, late cytolytic, and transformation stages. FFE = feather follicle epithelium.
typically administered shortly post-hatch or in ovo to
allow chicks to become immunized (requires 7 to 14 d
for full protection) before heavy exposure to the virus
in adult chicken flocks. A major flaw of the current
vaccination strategies is that they do not produce ster-
ile immunity, i.e., virulent strain infection, replication,
and transmission still occur in vaccinated birds (Nair,
2005).
The precise mechanism(s) of vaccine-related immu-
nity is not known, but contributing factors may be
reduced growth rate of MDV in the host (Purchase
and Okazaki, 1971) and prevention of virulent MDV
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immunosuppressive effects on the host (Islam et al.,
2002). Infection of T and B lymphocytes by the vaccine
strain(s) potentially interferes with the infection pro-
cess of virulent MDV and contributes to the protective
effect (Tischer et al., 2002); however, supplementary
mechanisms are likely involved (Witter, 1984; Oster-
rieder et al., 2006). Lee and colleagues (1999) conducted
in vivo studies to determine if MD vaccination impacted
the distribution of virulent MDV among T lympho-
cytes, through PCR (viral load assessment) and plaque
assays (infectivity). Serotype 1 virulent MDV was pri-
marily found in CD4+ T lymphocytes, and lower titers
of virulent MDV were detected in vaccinated birds up
to one mo after infection, which encompasses both the
lytic and latent stages of the viral life cycle. The MDV
serotype 1 (Rispens) and 2 (SB-1) vaccines greatly dif-
fered in their overall titers and dissemination between
CD4+ and CD8+ T lymphocytes. Furthermore, vac-
cinated and challenged birds showed higher levels of
apoptosis among peripheral blood mononuclear cells as
compared to challenged-only birds (Lee et al., 1999),
suggesting that a component of the vaccine’s protec-
tive mechanism is reduction in the number of CD4+ T
lymphocytes.
It is currently understood that the Rispens/ CVI988
vaccine develops into mature virions at the host feather
follicle and sheds into the environment in large quanti-
ties, in a similar manner to virulent strains, and trans-
mits among chickens. Rispens was detected through
qPCR in peripheral lymphocytes after vaccination
(peak at 7 d post vaccination [dpv]) and in feather tips
as early as 7 dpv (peak at 14 dpv). A steady decline of
Rispens genome copy number in these tissues occurred
after 14 dpv while the presence of the virus in shed
dander steadily increased and peaked at 21 dpv (Islam
et al., 2013). More recent studies have differentiated
Rispens from oncogenic serotype 1 MDV by mismatch
amplification mutation assay and demonstrated that in-
sufficiently immunized (low dose vaccination) chickens
have higher loads of oncogenic MDV in the blood and
feather pulp as early as 21 dpi as compared to prop-
erly vaccinated birds (Gimeno et al., 2011, 2014). The
HVT and SB-1 vaccines are also actively shed from
host birds, starting around 7 dpv for HVT-vaccinated
birds and 12 dpv for SB-1-vaccinated birds. The SB-1
and HVT strains continued to be shed with the feather
dander for several months after vaccination and signif-
icantly reduced virulent MDV shedding in dander be-
tween 14 and 28 dpi (Islam and Walkden-Brown, 2007).
Thus, another component of the vaccinal benefit may
be interference with virulent MDV infection of the host
FFE and resultant decreased viral transmission. In-
terestingly, a non-producer T-lymphoblastoid cell line,
developed from the spleen of an HVT-vaccinated and
MDV-infected healthy chicken, contained latent HVT
and MDV genomes, and neither virus strain was re-
activated (returned to lytic stage) by altering culture
conditions (Hirai et al., 1981). The physical state of the
HVT genome in the lymphoblastoid cell line was not
determined. Two strains of HVT were found to be in
the latent stage of infection, as indicated by low viral
antigen expression, in the spleen of vaccinated chickens
as well (Fabricant et al., 1982).
Integration into the Host Genome
Early studies of host telomeric integration by
MDV Both linear and episomal forms of MDV are
found in infected host cells. The episome is the host
genome-independent form of the virus, and the linear
form is typically integrated within the host genome
(Delecluse and Hammerschmidt, 1993a). Latently in-
fected (non-producer) cell lines exhibit very little to no
extra-chromosomal circular or linear viral DNA and,
rather, consist of integrated MDV (Kaschka-Dierich
et al., 1979; Delecluse and Hammerschmidt, 1993a).
However, free linear viral genome, or processed yet
un-circularized MDV genomic DNA, is detected at
low levels in some transformed low-producer cell lines
(Kaschka-Dierich et al., 1979). Delecluse and Hammer-
schmidt (1993a) were the first to report, by cytoge-
netic methods, that MDV integrated into host chro-
mosomal DNA in transformed cell lines developed from
infected birds. Interestingly, the integration sites were
mostly found to be distally located at the telomeres
of the macrochromosomes (Delecluse and Hammer-
schmidt, 1993a). Integration into host DNA was sup-
ported by detection of doublet MDV fluorescence in situ
hybridization (FISH) signals from sister chromatids,
indicating viral DNA was replicated along with the host
genome. Integration loci mapping was limited to the
largest macrochromosomes due to a lack of identifying
features for the microchromosomes. Integration profiles
were recurrent from cell to cell within a line, yet differed
from the profiles found in other cell lines.
Host Genome Acquisition The MDV genome con-
tains several homologous host genes and telomeric
repeats, which were presumably acquired from the
chicken genome during the evolution of the gallid her-
pesvirus (Tulman et al., 2000; Petherbridge et al., 2004;
Niikura et al., 2006). These findings from virus se-
quencing studies provided further evidence of physi-
cal virus-host genomic interactions. Niikura and col-
leagues (2006) found that a serotype 1 MDV strain,
specifically an infectious Md11 BAC clone propagated
on duck embryo fibroblasts, contained a region from
the duck genome within the TRS region of its viral
genome. This sequence was likely acquired during viral
lytic replication, perhaps by recombination, as a latent
infection was not established in the duck fibroblasts.
Further lytic replication in vitro was not hindered by
the acquired duck genome sequence, as the duck substi-
tution MDV strain persisted through multiple passages
in chicken embryo fibroblasts (Niikura et al., 2006). Pre-
sumably, most acquired chicken sequences that have
persisted in the current MDV field strains confer an
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advantage (selection favoring the modified MDV) in vi-
ral infection and/or transmission.
AVIAN CELLULAR AND MOLECULAR
IMMUNOLOGY
Immune Cells Targeted by MDV and the
Host Immune Response
MDV replication occurs in macrophages as well as B
and T lymphocytes (Calnek et al., 1984). However, the
virus achieves latency and transformation primarily in
CD4+ T cells (Lee et al., 1999; Robinson et al., 2010,
2014, and references therein), although there is some
evidence for latent virus in B, CD4-CD8- or CD8+ T
lymphocytes. Viral integration into the host genome is
detectable in cells early post infection from the bursa,
thymus, and spleen—organs with large B and/or T lym-
phocyte populations (Robinson et al., 2014). The adap-
tive response is highly important to lytic virus clearing
post infection, due to the highly cell-associated nature
of MDV. However, the innate immune response of the
host to challenge has been found to play a critical role
in studies of inbred chicken lines with differing MD re-
sistance (Kaiser, 2010).
All MDV serotypes are known to reduce surface
expression of the Major Histocompability Complex
(MHC) B class I glycoproteins during viral lytic repli-
cation, which is thought to aid in immune response eva-
sion (Hunt et al., 2001). This reduction of cell surface
MHC molecules does not persist into latency, perhaps
because minimal viral gene expression and integration
into host telomeres are sufficient for evasion of host re-
sponses.
Resistance to Marek’s Disease - Bird
Genotypes and Host Gene Involvement
MDV is highly effective at inducing fatal tumor de-
velopment in susceptible birds within a few wks after
infection, unless the host is protected by in ovo or at-
hatch vaccination and/or is a highly resistant genotype
(Calnek, 2001). Selection methods for MD resistance in
commercial chickens that avoid inbreeding effects in-
clude mass selection after exposing a flock to a high
dose of the virus (infected environment or inoculation)
and family selection (Bacon et al., 2001). Family selec-
tion with inbreeding, which involves sibling crosses and
offspring-parent crosses after testing for disease resis-
tance, is the approach often used to develop MD resis-
tance/susceptibility research lines (Bacon et al., 2001).
The inbreeding results in a near identical genome se-
quence within each line, which is a useful feature for
genetic investigations. A few prime examples of lines
resulting from this breeding method are the MD resis-
tant line 63 and MD tumor susceptible line 72 as well as
line 15I developed at the USDA Avian Disease and On-
cology Laboratory (ADOL) (Waters and Fontes, 1960;
Crittenden et al., 1972).
MHC congenic lines, consisting of birds with 99.9%
identical genomes and different MHC-B haplotypes, are
often used to understand the role of the different hap-
lotypes on MD pathogenesis. For example, UC Davis
(UCD) congenic lines share the UCD 003 inbred ge-
netic background but each line has a unique B haplo-
type (Abplanalp et al., 1992; Bacon et al. 2001). Con-
genic lines are crossed to identify loci with a role in cer-
tain traits related to MD resistance. Recombinant con-
genic lines from crosses of ADOL lines 63 and 72 each
contain a unique segment from line 72. These congenics
have been tested for MD tumor incidence to identify
non-MHC genes with an impact on viral oncogenesis
(Yonash et al., 1999).
Genetic studies of MD resistance employing inbred
research lines uncovered a few major genes involved in
the resistance. It is well known that MHC genes con-
tribute, as explained by the impact of MHC genotype
on cell-mediated and humoral immune response and
the specificity of immune response to MDV and MD
transformed cells (Bacon et al., 2001). The MHC gene
family encodes immunity-related cell surface molecules
that are primarily involved in antigen presentation and
regulation of T lymphocytes. Importantly, the chicken
MHC-B and RfpY haplotypes are linked on GGA 16,
but segregate independently (Miller et al., 1996), as
they are separated by a large GC-rich region of un-
known sequence (Delany et al., 2009). Numerous studies
have established the influence of B haplotype on MD re-
sistance in chicken (Briles and Olsen, 1971; Briles et al.,
1977; Schat et al., 1994; Miller et al., 1996). However,
non-MHC genes are influential as shown by studies of
lines 63 and 72, which have the same MHC B∗2 hap-
lotype (Hunt and Fulton, 1998). There are mixed re-
sults on the influence of the MHC RfpY haplotype on
MD resistance (Bacon et al. 1996; Wakenell et al., 1996;
Vallejo et al., 1998).
Other non-MHC genes are also thought to con-
tribute to MD resistance through cellular interactions,
variations in MDV-targeted cells, innate immunity,
or cytokine regulation. Notably, MD-resistant and -
susceptible lines have similar prevalence of CD4+ T
lymphocytes during the lytic and latent stage of MDV
infection, but during the tumor development stage
CD4+ T lymphocytes remain predominant in suscep-
tible bird lesions and CD8+ T cells become predomi-
nant in resistant bird lesions. These data indicate that
gene(s) involved in CD8 T cell response to tumors may
aid in MD suppression (Burgess et al., 2001). Studies of
Cornell MD susceptible (S) and resistant (K) bird lines
also indicated the involvement of the ALVE chicken en-
dogenous viral genes on resistance (Aggrey et al., 1998).
It was established as early as the 1970s that
MD-resistant chickens with particular MHC haplo-
types were generally better immunized by the MD
vaccines (Spencer et al., 1974). Significant genotype
by vaccine interactions has been demonstrated when
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commercial (sufficiently high) doses of vaccine were ad-
ministered (Bacon and Witter, 1994). More specifically,
the vaccine’s protective efficiency was demonstrated to
be higher in resistant line 63 birds as compared to line
72 genotype birds (Chang et al., 2014).
Advances in chicken genomics and genomic tech-
nology (sequencing, association studies, etc.) have al-
lowed researchers to comb the entire genome for genes
and pathways influencing MD resistance. QTL map-
ping (Bumstead et al., 1997; Vallejo et al., 1998; Yonash
et al., 1999) and subsequent comparative genomics for
loci identification (Burt et al., 1999) as well as DNA
microarrays (Heidari et al., 2010; Hu et al., 2015) have
all been employed to identify loci relevant to MD. Vac-
cination and selective breeding approaches for chicken
immunization and disease resistance are beginning to
exploit data on avian immune responses, the MHC, and
cytokines as well as genomic data to optimize efficiency
(i.e., innate immunity enhancement and modification)
and scope (i.e., optimize number of strains and/or
pathogens protected against) (Kaiser, 2010). However,
further research and testing of these genomic and im-
munology data-enhanced approaches will be necessary
to protect chickens against more virulent MDV strains
and other pathogens (Nair, 2005; Gimeno, 2008).
MDV LIFE CYCLE – MOLECULAR AND
CELLULAR DYNAMICS
Introduction to the Herpesvirus Life Cycle
Herpesviruses are double-stranded DNA viruses and
mature virions consisting of linear genomes contained
within an icosahedral capsid. Upon infection of tar-
get host cells, the linear genome becomes a covalently
closed circular episome and proceeds to a lytic repli-
cation stage, consisting of high gene expression and
production of viral progeny, or to latency, in which
gene expression is minimal and virus is not actively
produced.
Cytolytic Replication – Mechanisms, Gene
Expression, and Genome Configuration
For most herpesviruses, genome circularization oc-
curs within 30 min of infecting a host cell and is fol-
lowed by lytic replication (Boehmer and Nimonkar,
2003; Morissette and Flamand, 2010). Rolling circle
replication produces tandem head-tail viral genome
concatemers. The initiation of this process relies on
the presence of signaling sequences or origins of repli-
cation. The generated concatemers in the nuclei are
cleaved and packaged into pre-formed capsids (Boehmer
and Nimonkar, 2003). The peak of the lytic replica-
tion stage after MDV infection occurs around 3 to 7
dpi (Shek et al., 1983; Osterrieder et al., 2006, and
references therein). Important cytolytic-expressed viral
genes include the interleukin 8 homolog (vIL8) gene,
which functions as a chemoattractant of chicken pe-
ripheral mononuclear cells in chicken (Parcells et al.,
2001), and the viral lipase homolog (vLIP) gene, which
contributes to efficient viral replication in infected
cells (Kamil et al., 2005). Infection with mutant MDV
strains with deletions of vIL8 leads to decreased lytic
replication and oncogenicity, although some MD tumors
developed. The vIL8-deleted MDV is still able to tran-
sition into latency, indicating that it contributes to the
lytic stage but is not required for latency or transfor-
mation (Parcells et al., 2001).
Hunt and colleagues (2001) detected reduced cell sur-
face MHC class I (BF) glycoprotein expression in 60%
of infected UA04 cells undergoing MDV lytic replication
as well as all UA04 and MSB1 tumor cells with reac-
tivated virus. However, intracellular BF protein levels
were not significantly altered in the MDV-infected cell
lines, thus interference with BF transport to the cell
membrane was predicted to be the mechanism behind
reduced surface expression (Jugovic et al., 1998). This
effect was not observed in latently infected chicken cells,
perhaps because reduced overall gene expression and vi-
ral integration into the host DNA during latency (along
with other mechanisms) are sufficient to evade a host
immune response (Hunt et al., 2001).
Latency – Timing and Gene Expression
A common feature of herpesviruses is latency, which
is defined by viral infection without replication or pro-
duction of infectious virions (Stevens, 1989). MDV-
challenge in vivo studies indicate the presence of latent
virus in host cells around 7 dpi, primarily in CD4+ T
lymphocytes (Lee et al., 1999). MDV latent infection
can continue indefinitely in T lymphocytes throughout
the host while cytolytic replication and virion produc-
tion occur concurrently in the FFE. Most MDV latency
genes are located in the long and short repeat regions
of the genome (Sugaya et al., 1990), which encodes
Meq, vTR, the LAT family, and numerous MDV-1 mi-
croRNAs (miRNAs) (Burnside et al., 2006). Latency-
associated transcripts (LATs) are characteristically ex-
pressed by latent MDV; however, there exist no clear
data on the level of LAT expression or number of tran-
scripts (Osteriedder et al., 2006, and references therein).
The LAT family is also known to be highly expressed
in MD lymphomas (Ross et al., 1997). Both latently in-
fected and transformed cells possess histone modifica-
tions (repressive) at the origin of lytic replication and
(activating) at the Meq oncogene and miRNA cluster
(Brown et al., 2012). For many herpesviruses, including
MDV, reactivation of latent virus can lead to a return
of disease symptoms.
Cellular Transformation by MDV
The precise relationships of the latency and tumori-
genesis stages are currently unknown (Nair, 2013),
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and an important question persists: must MDV
latency precede transformation? There is ample sci-
entific evidence of temporal and behavioral overlap
between these 2 stages, and they also have the shared
feature of telomere-integrated MDV. Additionally, it
has been suggested that only some latently-infected
CD4+ T lymphocytes undergo transformation and even
fewer will generate the predominant transformed cell
lineages found in a late-stage MD lymphoma (Cal-
nek, 2001; Robinson et al., 2010, 2014). However,
mystery remains regarding the switch from latent in-
fection to T-lymphocyte transformation in the vis-
ceral organs of susceptible, unvaccinated host birds
(Nair, 2005).
As discussed above, research suggests MDV integra-
tion into the host genome is involved in tumorigenesis.
In other systems, hepatitis B and papilloma virus 18
also integrate into the genomic DNA of host cells be-
fore transformation is detected (Popescu et al., 1990).
Host telomere integrated MDV is a key feature of MD
lymphomas (Robinson et al., 2010, 2014). Cytogenetic
studies of early- and late-stage MD tumors found that
92.8% of the observed dividing cells contained only the
telomere-integrated form of MDV, indicating a signif-
icant relationship between viral integration and MD-
induced tumors/tumorigenesis (Robinson et al., 2014).
Furthermore, birds challenged with mutant- or deleted-
telomeric repeat MDV strains, which lack the ability to
integrate into the host telomeres, had significantly de-
creased lymphoma development. This result provided
further evidence of a link between MDV integration into
host telomeres and achievement of cellular transforma-
tion (Kaufer et al., 2011a).
MDV Genes Involved in Tumorigenesis Several
viral genes involved in oncogenesis have been identi-
fied within the MDV genome (Table 1). MDV miRNAs,
mapping to genes such as Meq (Burnside et al., 2006),
are known to be expressed in both MDV-induced tu-
mors and lymphoblastoid cell lines. Integration of MDV
into the host genome also appears to play a role in
the viral latency and tumorigenesis stages, rather than
being an incidental occurrence (Desfarges and Ciuffi,
2012; Robinson et al., 2014).
The Meq oncogene is one of the most thoroughly
studied MDV genes and is known to play a key role in
MDV-induced T cell lymphomagenesis, in combination
with other transcription factors, through host and vi-
ral gene expression modifications (Brown et al., 2009).
Meq encodes an abasic leucine zipper transcriptional
factor with favored dimerization with the cJun onco-
protein (cJun-Meq) and itself (Meq-Meq) (Qian et al.,
1996). The dimerized form of Meq impacts expression of
cellular anti-apoptotic factors and viral transformation-
associated genes and binds to cell cycle control factors
and MERE promoter sites to up-regulate its own ex-
pression (Liu et al., 1999; Osterrieder et al., 2006). Meq
is expressed in MD tumors and lytically infected T lym-
phocytes (Jones et al., 1992). When birds are infected
with Meq-deleted (ΔMeq) MDV (lacking both copies),
tumors do not develop (Silva et al., 2010) and viral
telomeric integration is not observed in the primary im-
mune tissues (Robinson et al., 2014). A functional copy
of the Meq gene is absent in MDV serotypes 2 and 3
and, thus, these strains do not express the oncoprotein
upon infection, replication, or latency. When compar-
ing the Meq gene of the attenuated Rispens/ CV1988
MDV vs. serotype 1 oncogenic MDV, a 178bp sequence
(domain duplication) was found to be inserted into the
CVI988 genome, which led to a frameshift mutation of
a transactivation domain (Lee et al., 2000b).
Another MDV gene that contributes to oncogen-
esis is the vIL8 homolog, encoded in the UL re-
gion of the genome. vIL8 functions as a chemoattrac-
tant of chicken peripheral mononuclear cells, which
includes lymphocytes, monocytes, and macrophages.
In vitro studies indicated that vIL8 induces chemo-
taxis of B lymphocytes, as well as CD4+ and CD25+
T lymphocytes, all of which are targets of MDV in-
fection (Engel et al., 2012). Within in vivo studies,
a vIL8-deleted mutant MDV strain resulted in de-
creased lytic replication and oncogenicity in the host,
although some MD tumors developed (Parcells et al.,
2001).
The viral homolog of the chicken telomerase RNA
subunit (TR), known as vTR, is located within the
IRL/TRL regions of the MDV genome (Delany and
Daniels, 2003; Fragnet et al., 2003). The high de-
gree of homology between vTR and chicken TR is
interpreted to be evidence of selective pressure to
maintain the TR sequence. There is evidence of vTR
contributing to MDV-induced cellular transformation
(Trapp et al., 2006) and speculation that vTR expres-
sion may have anti-apoptotic properties in latently in-
fected cells (Osterrieder et al., 2006). A vTR-knockout
and a vTR-mutated (with non-typical telomere re-
peats) MDV strain were severely impaired in their
ability to induce lymphomas in vivo, as indicated
by greatly reduced (>60%) tumor incidence and size
(Kaufer et al., 2011b). Lytic replication was not al-
tered as compared to wild-type MDV. Reversion of the
vTR sequence to wild-type, which restores its interac-
tions with telomerase reverse transcriptase (TERT),
led to a restoration of viral-induced tumorigenesis in
host birds. Thus, it was concluded that telomerase
activity must be a necessary component to transfor-
mation by MDV. In vitro, the DF-1 chicken fibrob-
last cell line adopted a transformation-like phenotype
when vTR was constitutively expressed. Interestingly,
vTR in combination with chicken TERT (chTERT)
leads to greater telomerase activity than chTR with
chTERT (Fragnet et al., 2005). Notably, the non-
oncogenic Rispens vaccine contains a mutation in the
vTR gene, which leads to reduced function (Fragnet
et al., 2005). It remains of interest to establish the ex-
tent to which host telomere biology, including telom-
ere maintenance (described below for chicken), is in-
volved in vTR-associated transformation (Trapp et al.,
2006).
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Reactivation of MDV Lytic Replication in
Latently Infected Cells
Reactivation of MDV involves a recurrence of high
viral gene expression and the viral genome replication
process in a formerly latently infected host lymphocyte.
In host birds, MDV reactivation from latency may nat-
urally occur around 2 wk post-infection, which is a par-
ticularly important event in migratory T lymphocytes
near the feather follicles. MDV-reactivation aids the in-
fection of FFE, from which mature virions will develop
and shed with the host dander.
During latency, lytic replication-inducing gene ex-
pression is suppressed and apoptosis of the host, la-
tently infected T lymphocyte, is blocked by viral mech-
anisms. As discussed, the Meq oncogene plays a crit-
ical role in activation of transformation/latency genes
and repression of lytic genes. During reactivation, Meq
splice variants that lack the domains involved in trans-
activation and -repression are expressed, permitting a
return to rolling circle replication and high gene ex-
pression in the host cell. It is also known that the cyto-
plasmic phosphoprotein pp38 is highly expressed dur-
ing lytic replication and reactivation (Baigent et al.,
1998), particularly in MD susceptible birds. It also has
been found that the presence of telomeric repeats in the
MDV genome is crucial for MDV reactivation (Kaufer
et al., 2011a). The trigger mechanism of reactivation
is not fully understood, but may involve reduction of
cytokines (Parcells et al., 2003).
TELOMERES AND TELOMERASE – ROLES
IN THE HOST CHICKEN AND MDV
INFECTION
Telomeres and Telomerase
Telomeres are nucleoprotein caps on the ends of lin-
ear chromosomes in eukaryotes (Zakian, 1995). They
serve as the solution to the problem of DNA-end loss
after each round of cell division. The eukaryotic telom-
eric repeats are often 5 to 10 nucleotides and GC-rich,
and serve as binding sites for the proteins that cap the
DNA ends (De Lange, 2005). The enzyme telomerase,
which consists of the TERT and a TR subunit (that
provides the telomere template) functions to elongate
the telomeric sequence by a specialized form of reverse
transcription and counter telomeric erosion that occurs
in each round of DNA replication (Greider and Black-
burn, 1987; Greider and Blackburn, 1989; Blackburn,
2001). TERT and TR expression levels impact the pres-
ence and activity levels of telomerase (Fragnet et al.,
2005). Telomerase is not detected in somatic cells but
is highly active in stem cells, germ line cells, and lym-
phocytes in humans (Hiyama et al., 1995). Telomerase
activity and changes in telomere biology also are as-
sociated with malignant transformation and immortal-
ization (Kim et al., 1994; Artandi and DePinho, 2010).
In fact, telomere stabilization through elevated telom-
erase activity and disruption of the “normal telomere
clock” can play a significant role in metastatic tumor
cell immortality (Harley et al., 1994; Shay et al., 2001).
Chicken Host Telomere Biology
In chicken, the telomeres consist of repeated
TTAGGGn DNA sequences (Delany et al., 2003). Three
overlapping classes of chicken telomeric sequence have
been identified that vary by length and chromosomal
location—namely, Class 1 (0.5 to 10 kb), Class 2 (10
to 40 kb), and Class 3 (40 kb to 2 Mb). Despite its
smaller genome size, the chicken genome has 10 times
more telomeric sequence than the human genome and
includes a set of ultra-long (aka mega-telomere) arrays
with the longest telomeres observed in any vertebrate
species, making avian telomere biology a particularly
interesting field of research (Delany et al., 2003). Cyto-
genetic (Nanda and Schmid, 1994; Solovei et al., 1994;
Delany et al., 2007) and molecular analyses (Delany
et al., 2000) revealed the length variation of chicken
telomeres as well as the existence of interstitial telom-
eres and the unique mega-telomeres. In chicken, the
telomeres were found to shorten after multiple cell di-
visions as in human, and this correlated with down-
regulation of telomerase activity in post-natal somatic
tissues (Delany et al., 2000; Taylor and Delany, 2000;
Swanberg et al., 2010). Telomere shortening or irregular
maintenance of telomeres in chicken cells is associated
with tumorigenesis or transformed cell types (Swanberg
et al., 2010, and references therein).
Telomeric Repeats and the Viral
Telomerase RNA Gene in the MDV Genome
Viral terminal repeats and cellular telomeres are sim-
ilarly crucial for genome maintenance and stability, par-
ticularly during replication processes. In fact, viral ter-
minal repeats play a role in genomic DNA stability for
many linear DNA viruses. Terminal repeats also con-
tribute to a range of other factors, including viral inte-
gration and packaging (Deng et al., 2012 and references
therein).
MDV harbors 2 forms of telomeric repeat arrays (con-
sisting of the TTAGGGn sequence) in its genomic ter-
mini (upon cleavage to the linear form), specifically
multiple (consisting of up to 100) and short (exactly 6)
repeats (Kaufer et al., 2011a; Greco et al., 2014). Both
the short and longer repeat arrays are located between
the RL and RS segments of the MDV genome (Figure 1)
and the cleavage site of concatemeric MDV is adjacent
to the short telomeric repeats region (Volkening and
Spatz, 2013). The role of the viral telomeric repeats is
hypothesized to be 1) service as a mini-chromosome cap
or 2) contribution to the capacity of the viral genome
to be packaged into the host genome via recombina-
tion or a telomerase-based pathway. There is evidence
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that the latter role applies to MDV (Osterrieder et al.,
2014) and that telomeric integration allows the MDV
genome to be replicated and distributed to progeny
cells during host cell proliferation. Telomere sequence
in the MDV genome also appears to be key in the pro-
cessing of replicated concatemers of viral DNA (Kishi
et al., 1991). Notably, the absence of MDV telomeric
repeats severely decreases viral replication, integration,
tumorigenesis, and reactivation of latent MDV in vivo
(Jarosinski et al., 2006; Kaufer et al., 2011a; Greco
et al., 2014).
The Mechanism of MDV Telomeric Integration
MDV integrates into the host genome, likely in the
form of a long concatemer of viral genomes as indicated
by cytogenetic and molecular studies (Delecluse and
Hammerschmidt, 1993a; Kaufer et al., 2011a; Robin-
son et al., 2010, 2014). The precise details of the MDV
integrating mechanism, including whether it exploits
the host telomere extension pathway and/or homolo-
gous recombination, are yet to be determined. However,
there is a growing amount of data on the necessary vi-
ral components in the integration process (Osterrieder
et al., 2014). The lack of a cell population with the
telomere-integrated only phenotype upon infection by
the ΔMeq MDV strain (see phenotypes described be-
low) may indicate a role for the Meq oncogene in estab-
lishment of this state of MDV in activated lymphocytes
(Robinson et al., 2014). Also, a vTR-mutated MDV
strain lost the ability to induce tumors in vivo, lead-
ing to speculations over the role of vTR in telomeric
integration of MDV (Osterrieder et al., 2006).
The MDV integration mechanism likely involves the
viral telomeric repeat arrays (Kaufer et al., 2011a;
Greco et al., 2014). MDV strains with a mutated or
deleted version of the telomeric repeats in their genome
failed to integrate at the host telomeres, as indicated by
Southern blot and FISH analyses (Kaufer et al., 2011a).
Greco and colleagues (2014) found that mutated short
telomeric repeats reduced viral replication and integra-
tion efficacy in vivo. However, these effects on the viral
life cycle were not observed as strongly in an in vitro
system, and a precise wild-type repeat length, but not
sequence, was necessary for replication to occur. Telom-
eric repeat sequence alteration also impacted MD tu-
mor incidence and transmission in vivo, and in the few
tumors that developed the number of MDV integra-
tion sites were reduced by 2-fold as compared to the
wild-type and revertant virus (Greco et al., 2014). It
should be noted that multiple telomeric repeats (vs.
short) were found to play a more significant role in
integration.
Telomere and Telomerase Changes Induced by
MDV Infection The changes in host telomere biology
or telomerase activity that result in cellular transforma-
tion can be induced by viral infection (Counter et al.,
1994; Horikawa and Barrett, 2003). In MDV infection,
telomeric integration has a causal link to tumorigenesis,
perhaps relating to telomere dysfunction among other
factors (Deng et al., 2012). The MDV vTR has a func-
tional promoter and, resultantly, induces telomerase ac-
tivity in TR-/- knockout murine cells and is naturally
expressed in the peripheral blood lymphocytes of MDV
challenged and vaccinated chicken. The telomerase ac-
tivity in the knockout line is particularly compelling
as it provides evidence of the functionality of vTR
in a heterologous telomerase complex. vTR-knockout
MDV was severely impaired in its ability to induce
lymphomas in vivo, as indicated by greatly reduced tu-
mor incidence and size in chickens (Trapp et al., 2006).
It also has been determined that vTR presence in the
MDV genome can lead to lymphoma development in
a telomerase complex independent manner, i.e., cells
expressing a mutant-vTR that does not functionally
complex with TERT were transformed in vivo, as well
(Kaufer et al., 2010).
CYTOGENOMIC MDV-HOST INTERACTIONS
Overview of MDV Cytogenetic Methods
Molecular and cytogenetic studies of MD have been
significantly enhanced by the availability of viral and
chicken genomic DNA clones (Schumacher et al., 2000;
Lee et al., 2003; Petherbridge et al., 2003; Hillier et al.,
2004; Petherbridge et al., 2004; Baigent et al., 2006;
Silva et al., 2010) and genome sequence data (Lee et al.,
2000a; Izumiya et al., 2001; Kingham et al., 2001; Spatz
et al., 2007). The clones provide a tool for strain- or
region-specific labeling of DNA while the sequence data
allow more in-depth exploration of genetic content, reg-
ulation, and interactions, as well as advances compara-
tive genomics. The primary cytogenetic technique em-
ployed to investigate viral and host genome interactions
has been FISH, applied to host mitotic metaphase chro-
mosomes. Southern blot hybridization has its own ad-
vantages for integration studies but can miss low copy
number integration, while FISH offers a more sensitive
and accurate viral detection approach that is reliable
and cell-specific (Leenman et al., 2004; Reisinger et al.,
2006; Haugg et al., 2014).
MDV Phenotypes and Infection Stages
Our understanding of the genomic interactions be-
tween MDV and its host and how these interactions
impact viral pathogenesis, transmission, and tumorige-
nesis has been improved by cytogenetic studies. Robin-
son et al. (2014) characterized 4 distinct viral genome
status phenotypes (see Figure 3) in dividing lympho-
cytes of the primary and secondary immune organs be-
tween one and 21 dpi employing FISH with a specific
MDV-BAC probe. The 4 phenotypes were 1) MDV-null,
lacking MDV signals in the nucleus or around the chro-
mosomes, 2) MDV chromosome-associated, MDV flu-
orescence signals surrounding the host chromosomes,
3) MDV chromosome-associated/integrated, presence
of associated signals as well as MDV signals integrated
into the sister chromatids at one or more telomeres,
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Figure 3. Marek’s disease virus-chicken host genome interaction phenotypes. The phenotypes shown indicate the interactions and status of
the herpesvirus with regard to the chicken host genome, in mitotically dividing cells from the immune organs of MDV-challenged birds (see text
for additional descriptions). (a) MDV-null phenotype, lacking MDV FISH signals (FITC, green) in the nucleus or around the chromosomes
(DAPI, blue). (b) MDV chromosome-associated phenotype, consisting of diffuse MDV fluorescence signals surrounding the host chromosomes.
(c) MDV chromosome-associated/integrated phenotype, defined by the presence of diffuse, host DNA associated MDV signals as well as bright
and punctate signals, signifying MDV integrated into host sister chromatids at one or more telomeres. (d) MDV chromosome-integrated only
phenotype, consisting of the distinct, punctate MDV FISH signals at the telomeres with no other signals detected.
and 4) MDV chromosome-integrated only, presence of
the distinct, punctate signals at the telomeres with no
other MDV signals.
The relevant timepoints and stages of infection in
the serotype 1 MDV life cycle are well described (Os-
teriedder et al., 2006; Schat and Nair, 2008), which
enables correlation of MDV-host phenotypes to the
known temporal disease stages and viral “activities.”
MDV-null cells lack MDV (episomal or integrated). The
MDV chromosome-associated phenotype suggests cells
are in the cytolytic stage (virus replicating indepen-
dently of the host genome). The MDV chromosome-
associated/telomere-integrated phenotype reflects the
presence of replicating episomal virus simultaneously
existing in cell(s) with viral DNA that has integrated
into the host genome and, finally, the integrated-only
MDV phenotype represents a latently infected or trans-
formed cell, cleared of replicating virus with the host
chromosomes harboring linear MDV genomes (Figures
2 and 3). In a time course study (1 to 21 dpi, Robinson
et al., 2014), the telomere-integrated only viral pheno-
type (latency and transformation associated) generally
increased over time in all immune tissues, particularly
in the spleen, while the chromosome-associated pheno-
type decreased over time in all tissues. There was re-
markable heterogeneity in chromosomal location and
number of MDV integrations initially (in non-tumor
cells of the spleen), but all were telomeric and typi-
cally at only one telomere arm per chromosome. South-
ern blot analyses showed DNA-junction fragments con-
taining both host-telomeric and MDV DNA from in-
fected lymphoblastoid cells, confirming viral integration
(Kaufer et al., 2011a).
Temporal Dynamics of MDV in the Host
Chromosomal Association During Timing of Cy-
tolytic Replication During the early cytolytic infec-
tion, the virus is actively spreading among host immune
cells, and the MDV genome is replicated and packaged
into infectious virion particles. The viral load in the
immune tissues peaks during this initial stage (shortly
after initial exposure to the infectious dander). Robin-
son and colleagues (2014) found evidence of serotype 1
MDV lytic replication throughout the immune organs
via cytogenetic detection as early as one dpi, which is
earlier than previously reported (4 dpi by Baigent and
Davidson, 1999). This finding emphasizes that FISH
detection of viral genome status is highly sensitive
MAREK’S DISEASE VIRUS - CHICKEN INTERACTIONS 423
(Robinson et al., 2014). The thymic and bursal immune
tissues, which consist of populations of primarily T
and B lymphocytes, respectively, exhibit peak levels of
MDV chromosome-associated phenotype cells around
4 dpi, which continuously declined by 14 and 21 dpi.
These results are consistent with data indicating a peak
of lytic replication between 4 and 7 dpi (Baigent and
Davison, 2004). Evidence that MDV integrates prior to
the latent stage (7 dpi) of MD pathogenesis supports
our knowledge that indeed stages overlap within and
among cells.
Telomeric Integration During Timing of Latency
Integration is a characteristic feature of the MDV life
cycle; however, the necessity of integration to the vari-
ous aspects of the viral life cycle is difficult to establish
exactly. Important questions include: Is integration re-
quired for viral latency and does such contribute to per-
sistence? Is integration essential for transformation and
tumorigenesis? Integration of viral DNA appears not to
be an incidental occurrence but, rather, has a role in the
viral latency and tumorigenesis stages (Desfarges and
Ciuffi, 2012). In MDV there is clearly a temporal over-
lap between the established timing of latency (around 7
dpi, but involving temporal overlap with the lytic stage)
from molecular data (Lee et al., 1999; Nair, 2013 and
references therein) and MDV telomere-integration from
cytogenetic data (Robinson et al., 2014). This suggests
a relationship between integration of the virus and the
lytic to latency transition. Furthermore, the timing of
the latency to tumorigenesis (14 to 21 dpi) transition
during MDV infection correlates with a reduction of the
associated/integrated viral phenotype (such reduction
related to the clearing of the virus) and an increase
in the chromosome-integrated only phenotype among
the dividing immune cells (Robinson et al., 2014). The
cells of the spleen exhibited particularly high levels of
the MDV integrated only virus phenotype after 7 dpi.
Spleen cell populations consist of B and T lymphocytes,
as well as macrophages and other lymphoid and non-
lymphoid cells (Olah et al., 2014); however, it has not
been determined if there is a bias of MDV integrating
into chromosomes of T vs. B lymphocytes. The overlap
in timing and events established by the molecular and
cytogenetic data are intriguing, but it is not yet known
whether the act of integration into host telomeres is
necessary to achieve latency or if viral integration re-
quires latency-related events to occur (chicken vs. the
egg).
MDV Integration and Oncogenesis Both in vitro
and in vivo studies indicate an integral biological rela-
tionship between MDV integration and cellular trans-
formation or MD lymphoma formation in susceptible
hosts. Almost the entire population of mitotically divid-
ing lymphocytes (>90%) analyzed from primary MD-
lymphomas have the MDV telomere-integrated only
phenotype, consisting of integrations at multiple telom-
eric site(s) (Robinson et al., 2010, 2014). Minimal
amounts of free episomal virus (i.e., lytically repli-
cating) were identified in tumors. Furthermore, birds
infected with a non-integrating, mutant MDV strain
had decreased to no lymphoma development—further
demonstration of an association between MDV integra-
tion and achievement of cellular transformation (Kaufer
et al., 2011a,b).
Analysis of the unique telomeric integration sites of
MDV within and among tumors suggested that both
monoclonal and polyclonal tumors (Robinson et al.,
2010) form in challenged, susceptible birds. A mode of
5 MDV telomere-integration sites per nuclei was identi-
fied in the tumors of MD-susceptible heterozygous line
(USDA-ADOL 1515 × 71 F1) chicks, with a range of one
to 8 integrations (Robinson et al., 2010). Doublet virus
FISH signals were commonly detected at the chromo-
some ends, indicative of telomere-integrated MDV in
both sister chromatids and suggesting that the virus
replicates along with the host chromosomes (Robin-
son et al., 2010). Fluorescence signal strength varia-
tion among different viral integration loci was detected
within and among individual cells and lymphomas, in-
dicating that a variable number of tandemly repeated
viral genomes in the host DNA occurs from one in-
tegration event to the next. However, there was signal
consistency for a particular integration locus within an-
alyzed lymphoma. Data from the Robinson et al. (2010)
study did not support a preference of MDV towards in-
tegration at the mega-telomeres, although integration
always occurs within or near the telomeres. Also, ane-
uploid and tetraploid tumor cells were observed similar
to that reported for many human leukemia and lym-
phomas.
With regard to whether integrations are random or if
there exists preferred or targeted integration into spe-
cific host chromosomes, a statistically-supported “pref-
erential chromosome” for MDV integration(s) was not
detected among the analyzed lymphomas. However,
there were strong tendencies towards MDV integration
into the telomeres of GGA 9 (encodes chicken TR) as
well as GGA 4 (encodes chicken IL-8 gene), GGA 6,
GGA 12 and GGA 20 (Robinson et al., 2010).
The question of clonality (i.e., lineage relationship of
cells within or among tumors) was addressed through
examination of the profile of chromosomal integrations
among cells of a tumor and in other tumors from the
same bird. The result was mixed; a majority of tu-
mors exhibited profiles indicating monoclonal tumor
origins, yet in other cases polyclonal tumors were de-
tected (Robinson et al., 2010). By another method, T
lymphocyte spectratyping of MD lymphomas, limited
clonality was indicated (Mwangi et al., 2011). MD is
well known to be a highly individualistic disease with
a great degree of inter-individual variation; thus, these
results are not entirely surprising for a virally-induced
cancerous condition.
The MDV integration profiles of early- to late-stage
MD tumors from GA-challenged birds were compared
(Robinson et al., 2014) and 3 categories of tumor
phenotypes based on their viral integration profiles
were uncovered. These included 1) highly heterogeneous
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(5 to 8 different integration profiles wherein less than
50% of cells displayed the most frequent profile), 2)
moderately heterogeneous (5 to 7 different profiles with
50 to 70% of cells exhibiting the most frequent profile),
and 3) homogenous (2 to 5 different profiles wherein
greater than 70% of cells shared the most frequent
profile). Interestingly, early-stage tumors, collected at
21 dpi, exhibited the heterogeneous phenotype. Con-
versely, late-stage tumors, collected at 61 and 73 dpi,
had only the homogenous tumor phenotype. Our pro-
posed model is that early-stage tumors represent a col-
lection of recently transformed T lymphocytes, many
of which do not persist or contribute to the cell lineage
of a late-stage tumor. The increased uniformity of cells,
in terms of viral integration phenotype, in late-stage
tumors (i.e., one lineage tends to dominate during tu-
mor growth and metastases) is indicative of a selection
process during tumorigenesis.
Reactivation and MDV Phenotype Although MD
lymphomas consist principally of latently-infected and
transformed cells, increased numbers of cells with lyt-
ically replicating virus (free linear form) are detected
from MD primary lymphomas upon different culture
conditions (Dunn and Nazerian, 1977; Calnek et al.,
1981; Delecluse et al., 1993c; Robinson, 2013). Cy-
togenetic analysis of the latently infected UA04 T
lymphocyte line (Dienglewicz and Parcells, 1999) fol-
lowing incubation with bromodeoxyuridine showed
multiple, speckled FISH signals surrounding the MDV-
integrated chromosome (absent in control cells). This
starburst of dispersed viral FISH signals is interpreted
as escaped, replicating MDV genomes (Robinson, 2013;
Schmid et al., 2015 Figure 2 in the section entitled
“Host-Viral Genome Interactions in Marek’s Disease”).
Thus, MDV may not only use integration as a means
for avoiding immune detection (latency), but also as
a mode of persistence in the host with the means to
“escape” from the host genome and return to the repli-
cation phase of its life cycle, i.e., reactivation (Figure 2
model). The ability to return to a state of productive
replication after integration presumes that the MDV
genome integrated intact and without rearrangement
into the host DNA. Clearly, further research is neces-
sary to support or refute such a model.
Novel Findings in MDV Cytogenomic
Dynamics
MD Vaccine Interactions with the Host Genome
The in vivo interactions of MD vaccines, specifically
Rispens/ CV1988, SB-1 and HVT, with the host
genome during the first 3 wk after vaccination also have
been investigated to understand if the vaccines can in-
tegrate (McPherson et al., in prep). The chromosome-
associated/integrated phenotype was detected post vac-
cination in spleen cell preparations, indicating that all
3 MD vaccine serotypes are capable of integrating into
host telomeres. This result was noteworthy considering
that the viral telomeric repeats are intact within all MD
vaccine genomes, but the Meq and vTR genes, which
are known to contribute to MDV integration, are ab-
sent from SB-1 and HVT genomes (Fragnet et al., 2003;
Kingham et al., 2001; Fragnet et al., 2005; Spatz and
Schat, 2011) and lack functional copies in the Rispens
genome (Trapp et al., 2006; Spatz et al., 2007). Inter-
estingly, the MDV telomere-integrated only phenotype
was not observed as found for serotype 1 viruses, similar
to a Meq-deleted MDV strain (see below).
Meq MDV Interactions with the Host Genome
A non-oncogenic ΔMeq MDV strain (Silva et al., 2010)
maintains a markedly high and sustained level of MDV
chromosome-associated signals in host immune tissues
(suggesting continuous replication) and does not estab-
lish the telomere-integrated only phenotype in host cells
between one and 21 dpi (Robinson et al., 2014). Thus,
this unique deletion strain is indeed capable of telomeric
integration, yet does not transition to integrated-only,
nor is it known to transform host lymphocytes in vivo
or possess a capacity for latent infection. These results
provided evidence that Meq expression and a transi-
tion to telomere-integration profiles alone (no episomal
form) by MDV in host nuclei are integral to the estab-
lishment of the latent infection and MD-induced trans-
formation. However, neither of these viral activities is
required for infiltration of the host immune cells, lytic
replication, or transmission.
CONCLUSION
MD is a significant, ongoing health issue for poultry
that has persisted despite the enormous body of high-
quality fundamental and applied research discoveries.
MD vaccines have resulted in a large degree of disease
control, yet we know MDV field strains are evolving.
It is important for continued research and resource ef-
forts to eradicate and manage this disease for the ben-
efit of this high-value agricultural resource. Simulta-
neously, research efforts around MDV can contribute
to the body of knowledge for cancer-causing human
viruses and herpesvirus-associated diseases.
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